Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTA Enanta Pharmaceuticals	$5.10 +3.4%	$6.30	$4.09 ▼ $17.24	$108.80M	0.69	284,969 shs	183,462 shs
MNMD Mind Medicine (MindMed)	$5.77 +5.7%	$6.54	$4.70 ▼ $10.44	$434.87M	2.54	1.40 million shs	1.17 million shs
PGEN Precigen	$1.39 +1.5%	$1.66	$0.65 ▼ $2.17	$408.72M	1.7	1.23 million shs	1.05 million shs
STOK Stoke Therapeutics	$7.69 +1.7%	$7.90	$5.35 ▼ $17.58	$415.86M	1.09	713,937 shs	837,492 shs

7 Top Nuclear Stocks To Buy Now

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTA Enanta Pharmaceuticals	+3.45%	+19.72%	-19.05%	-2.86%	-63.57%
MNMD Mind Medicine (MindMed)	+5.68%	+12.26%	-10.54%	-19.41%	-39.45%
PGEN Precigen	+1.46%	+8.59%	-16.77%	+25.23%	+6.11%
STOK Stoke Therapeutics	+1.72%	+17.94%	-13.30%	-17.84%	-34.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENTA Enanta Pharmaceuticals	4.0354 of 5 stars	3.4	1.0	4.7	2.1	4.2	0.6
MNMD Mind Medicine (MindMed)	2.1219 of 5 stars	3.6	2.0	0.0	2.5	0.8	0.6
PGEN Precigen	3.1762 of 5 stars	3.5	0.0	4.7	0.6	1.7	0.6
STOK Stoke Therapeutics	3.3726 of 5 stars	3.6	0.0	4.8	2.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTA Enanta Pharmaceuticals	2.80	Moderate Buy	$17.25	238.24% Upside
MNMD Mind Medicine (MindMed)	3.23	Buy	$25.11	335.20% Upside
PGEN Precigen	3.00	Buy	$7.00	403.60% Upside
STOK Stoke Therapeutics	3.13	Buy	$24.67	220.76% Upside

Current Analyst Ratings Breakdown

Latest ENTA, MNMD, PGEN, and STOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
3/20/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/19/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00 ➝ $47.00
3/19/2025	STOK Stoke Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
3/18/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
3/7/2025	MNMD Mind Medicine (MindMed)	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$27.00 ➝ $16.00
3/7/2025	MNMD Mind Medicine (MindMed)	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
2/19/2025	STOK Stoke Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
2/18/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $47.00
2/18/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
2/11/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00 ➝ $21.00

(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTA Enanta Pharmaceuticals	$66.59M	1.63	N/A	N/A	$5.24 per share	0.97
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$1.90 per share	N/A
PGEN Precigen	$3.93M	104.13	N/A	N/A	$0.48 per share	2.90
STOK Stoke Therapeutics	$36.56M	11.38	N/A	N/A	$3.57 per share	2.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.95	N/A	N/A	N/A	-157.57%	-75.53%	-27.30%	5/5/2025 (Estimated)
MNMD Mind Medicine (MindMed)	-$95.73M	-$2.08	N/A	N/A	N/A	N/A	-47.56%	-35.55%	5/6/2025 (Estimated)
PGEN Precigen	-$95.90M	-$0.48	N/A	N/A	N/A	-3,521.68%	-123.06%	-87.33%	5/13/2025 (Estimated)
STOK Stoke Therapeutics	-$104.70M	-$1.68	N/A	N/A	N/A	-629.90%	-54.45%	-40.77%	5/5/2025 (Estimated)

Latest ENTA, MNMD, PGEN, and STOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MNMD Mind Medicine (MindMed)	-$0.36	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	PGEN Precigen	-$0.08	N/A	N/A	N/A	$0.50 million	N/A
5/5/2025	Q2 2025	ENTA Enanta Pharmaceuticals	-$1.16	N/A	N/A	N/A	$15.96 million	N/A
5/5/2025	Q1 2025	STOK Stoke Therapeutics	-$0.42	N/A	N/A	N/A	$27.37 million	N/A
3/24/2025	Q4 2024	STOK Stoke Therapeutics	-$0.56	-$0.18	+$0.38	-$0.18	$4.20 million	$22.61 million
3/19/2025	Q4 2024	PGEN Precigen	-$0.06	-$0.04	+$0.02	-$0.06	$1.30 million	$1.19 million
3/6/2025	Q4 2024	MNMD Mind Medicine (MindMed)	-$0.33	-$0.41	-$0.08	-$0.41	N/A	N/A
2/10/2025	Q1 2025	ENTA Enanta Pharmaceuticals	-$1.16	-$1.05	+$0.11	-$1.05	$17.25 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTA Enanta Pharmaceuticals	N/A	5.47	5.47
MNMD Mind Medicine (MindMed)	0.09	9.00	9.00
PGEN Precigen	N/A	1.63	1.63
STOK Stoke Therapeutics	N/A	5.09	5.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTA Enanta Pharmaceuticals	94.99%
MNMD Mind Medicine (MindMed)	27.91%
PGEN Precigen	33.51%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ENTA Enanta Pharmaceuticals	13.89%
MNMD Mind Medicine (MindMed)	2.26%
PGEN Precigen	44.90%
STOK Stoke Therapeutics	11.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTA Enanta Pharmaceuticals	160	21.33 million	18.37 million	Optionable
MNMD Mind Medicine (MindMed)	40	75.37 million	71.68 million	Optionable
PGEN Precigen	190	294.04 million	161.37 million	Optionable
STOK Stoke Therapeutics	100	54.08 million	46.98 million	Optionable

ENTA, MNMD, PGEN, and STOK Headlines

Recent News About These Companies

FY2029 Earnings Estimate for STOK Issued By Leerink Partnrs

April 18 at 8:57 AM | marketbeat.com

FY2029 EPS Estimate for Stoke Therapeutics Raised by Analyst

April 18 at 3:33 AM | americanbankingnews.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of "Buy" by Analysts

April 17 at 2:12 AM | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from Brokerages

April 16 at 2:15 AM | americanbankingnews.com

Why Stoke Therapeutics, Inc.’s (STOK) Stock Is Up 7.69%

April 15 at 4:56 AM | aaii.com

Trexquant Investment LP Sells 58,718 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

April 13, 2025 | marketbeat.com

314,800 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Acquired by Norges Bank

April 13, 2025 | marketbeat.com

Stoke Therapeutics' (STOK) "Buy" Rating Reiterated at Needham & Company LLC

April 12, 2025 | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC

April 11, 2025 | marketbeat.com

Needham Keeps Their Buy Rating on Stoke Therapeutics (STOK)

April 10, 2025 | markets.businessinsider.com

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

April 1, 2025 | businesswire.com

Stoke Therapeutics remains significantly undervalued, says Canaccord

April 1, 2025 | markets.businessinsider.com

What is Chardan Capital's Forecast for STOK FY2025 Earnings?

March 28, 2025 | marketbeat.com

Cantor Fitzgerald Issues Positive Forecast for STOK Earnings

March 24, 2025 | marketbeat.com

Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

March 22, 2025 | finance.yahoo.com

What is HC Wainwright's Forecast for STOK Q3 Earnings?

March 22, 2025 | marketbeat.com

Leerink Partnrs Weighs in on STOK Q1 Earnings

March 22, 2025 | marketbeat.com

Q1 EPS Estimate for Stoke Therapeutics Lifted by Analyst

March 22, 2025 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by Brokerages

March 22, 2025 | marketbeat.com

Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 2,266 Shares of Stock

March 21, 2025 | marketbeat.com

Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Sells 3,884 Shares of Stock

March 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
By Leo Miller | March 21, 2025
View Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
Buffett’s Next Oil Bet: Why Occidental Is Different
By Jea Yu | April 8, 2025
View Buffett’s Next Oil Bet: Why Occidental Is Different
Can SoundHound AI Double? What the Fundamentals and Deals Reveal
By Gabriel Osorio-Mazilli | March 25, 2025
View Can SoundHound AI Double? What the Fundamentals and Deals Reveal
JPMorgan: The 'NVIDIA of Banking' Poised for More Gains?
By Gabriel Osorio-Mazilli | March 28, 2025
View JPMorgan: The 'NVIDIA of Banking' Poised for More Gains?
Top 3 S&P 500 Winners in a Losing Market
By Ryan Hasson | April 9, 2025
View Top 3 S&P 500 Winners in a Losing Market

ENTA, MNMD, PGEN, and STOK Company Descriptions

Enanta Pharmaceuticals NASDAQ:ENTA

$5.10 +0.17 (+3.45%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$5.11 +0.01 (+0.20%)

As of 04/17/2025 04:05 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Mind Medicine (MindMed) NASDAQ:MNMD

$5.77 +0.31 (+5.68%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$5.62 -0.15 (-2.51%)

As of 04/17/2025 06:06 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Precigen NASDAQ:PGEN

$1.39 +0.02 (+1.46%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$1.49 +0.10 (+7.12%)

As of 04/17/2025 06:07 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Stoke Therapeutics NASDAQ:STOK

$7.69 +0.13 (+1.72%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$7.30 -0.39 (-5.01%)

As of 04/17/2025 05:21 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time